Based on the results of this trial, on 22 June 2021, savolitinib was conditionally approved for the treatment of NSCLC with MET ex14 skipping alterations in patients who have progressed or are intolerant to platinum-based chemotherapy in China. This evidence concerns the gene MET and non-small cell lung carcinoma.